Harvard Bioscience, Inc.
HBIO
Positions held
Your positionsHBIO isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $37.01M | Enterprise value | $74.71M | Trailing P/E | — | Forward P/E | 12.60 |
| PEG | 1.31 | Price / book | 4.99 | Beta | 1.51 | Dividend yield | 0.00% |
| Revenue growth | 11.1% | Earnings growth | — | Gross margin | 58.2% | Operating margin | -2.9% |
| Profit margin | -11.9% | ROE | -89.9% | ROA | 1.6% | Debt / equity | 5.96 |
| Current ratio | 1.87 | Free cash flow | $5.30M | Analyst recommendation | none | Mean target | $7.50 |
| 52w high | $9.40 | 52w low | $3.80 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $22.7M | $20.8M | $23.7M | $20.6M | $20.4M | — |
| Op margin | -2.9% | -4.5% | 8.1% | 1.2% | -3.0% | — |
| Net income | -$2.9M | -$3.4M | -$2.8M | -$1.2M | -$2.3M | — |
| Gross margin | 55.6% | 59.0% | 59.7% | 58.4% | 56.4% | — |
| Gross profit | $12.6M | $12.2M | $14.2M | $12.0M | $11.5M | — |
| Operating income | -$0.7M | -$0.9M | $1.9M | $0.2M | -$0.6M | — |
- Revenue +10% vs prior quarter ($23M vs $21M).
- Gross margin 55.6% (was 59% prior quarter).
- Operating margin expanded to -2.9%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $86.5M | $94.1M | $112M | $113M |
| Op margin | 0.1% | -6.6% | 1.7% | -6.3% |
| Net income | -$56.7M | -$12.4M | -$3.4M | -$9.5M |
| Gross margin | 57.7% | 58.2% | 58.9% | 53.7% |
| Gross profit | $49.9M | $54.8M | $66.1M | $60.8M |
| Operating income | $0.1M | -$6.2M | $1.9M | -$7.2M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Harvard Bioscience Announces Creation of Scientific Advisory Board
2026-08-18 · Harvard Bioscience (HBIO) Q2 2026 Earnings Call Transcript
2026-08-11 · Harvard Bioscience, Inc. Q2 2026 Earnings Call Summary
2026-08-11 · Harvard Bioscience Inc (HBIO) (Q2 2026) Earnings Call Highlights: Revenue Surges 11% and ...
2026-08-11 · Harvard Bioscience beats Q2 estimates and raises 2026 revenue guidance
2026-08-11 · Harvard Bioscience: Q2 Earnings Snapshot
2026-08-11 · Harvard Bioscience Announces Second Quarter 2026 Financial Results
2026-07-28 · Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8:00 AM ET
Price (daily)
Full chart · RSI · MACD · patterns